Marker Therapeutics (MRKR) Construction in Progress (2020 - 2022)
Marker Therapeutics (MRKR) posted quarterly Construction in Progress of $4.1 million for Q1 2022, up 83.7% quarter-over-quarter from $2.2 million in Q4 2021.
Marker Therapeutics (MRKR) Construction in Progress (2020 - 2022) Analysis & Trends
Marker Therapeutics (MRKR) has reported Construction in Progress for 3 consecutive years, with $4.1 million the latest figure, recorded in Q1 2022.
- In Q1 2022, Construction in Progress changed N/A year-over-year to $4.1 million; the TTM figure through Mar 2022 stood at $4.1 million (changed N/A YoY), while the FY2021 annual figure was $2.2 million, down 67.26% from the prior year.
- Construction in Progress rose to $4.1 million in Q1 2022 per MRKR's latest filing, from $2.2 million in the prior quarter.
- Across five years, Construction in Progress topped out at $6.8 million in Q4 2020 and bottomed at $2.2 million in Q3 2021.
- Historically, Construction in Progress has averaged $3.8 million across 3 years, with a median of $3.4 million in 2020.
- On a YoY basis, Construction in Progress climbed as much as 52.17% in 2021 and fell as far as 67.26% in 2021.
- Marker Therapeutics' Construction in Progress stood at $6.8 million in 2020, then sank by 67.26% to $2.2 million in 2021, then surged by 83.7% to $4.1 million in 2022.
- Business Quant data shows MRKR's Construction in Progress at $4.1 million in Q1 2022, $2.2 million in Q4 2021, and $2.2 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.41 Bn | 131.56 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.14 Bn | 78.15 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 65.52 Bn | 60.34 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.21 Bn | 53.07 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 152.67 Mn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | - |
| 10 | Marker Therapeutics | 26.94 Mn | 15.01 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 4.09 Mn |
| Dec 31, 2021 | 2.23 Mn |
| Sep 30, 2021 | 2.20 Mn |
| Dec 31, 2020 | 6.80 Mn |
| Sep 30, 2020 | 4.60 Mn |
| Jun 30, 2020 | 2.63 Mn |